We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Albemarle (ALB - Free Report) closed at $164.93, marking a -3.34% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 1.05%, while the tech-heavy Nasdaq appreciated by 0.56%.
The stock of specialty chemicals company has risen by 18.55% in the past month, leading the Basic Materials sector's gain of 7.23% and the S&P 500's gain of 0.74%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 11, 2026. The company's earnings per share (EPS) are projected to be -$0.52, reflecting a 52.29% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.35 billion, up 9.58% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.9 per share and a revenue of $5.06 billion, indicating changes of +61.54% and 0%, respectively, from the former year.
Any recent changes to analyst estimates for Albemarle should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 180.18% rise in the Zacks Consensus EPS estimate. Currently, Albemarle is carrying a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 48.83. This represents a premium compared to its industry average Forward P/E of 16.91.
Investors should also note that ALB has a PEG ratio of 3.05 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Chemical - Diversified industry had an average PEG ratio of 3.05 as trading concluded yesterday.
The Chemical - Diversified industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 210, positioning it in the bottom 15% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Albemarle (ALB - Free Report) closed at $164.93, marking a -3.34% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 1.05%, while the tech-heavy Nasdaq appreciated by 0.56%.
The stock of specialty chemicals company has risen by 18.55% in the past month, leading the Basic Materials sector's gain of 7.23% and the S&P 500's gain of 0.74%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 11, 2026. The company's earnings per share (EPS) are projected to be -$0.52, reflecting a 52.29% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.35 billion, up 9.58% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.9 per share and a revenue of $5.06 billion, indicating changes of +61.54% and 0%, respectively, from the former year.
Any recent changes to analyst estimates for Albemarle should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 180.18% rise in the Zacks Consensus EPS estimate. Currently, Albemarle is carrying a Zacks Rank of #1 (Strong Buy).
Digging into valuation, Albemarle currently has a Forward P/E ratio of 48.83. This represents a premium compared to its industry average Forward P/E of 16.91.
Investors should also note that ALB has a PEG ratio of 3.05 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Chemical - Diversified industry had an average PEG ratio of 3.05 as trading concluded yesterday.
The Chemical - Diversified industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 210, positioning it in the bottom 15% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.